12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 75.3% to $1.49 during Friday's pre-market session. The company's market cap stands at $245.2 million. Cryo-Cell International (AMEX:CCEL) shares i
BenzingaApr 26 08:06 ET
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersAclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Processa Pharma (NASDAQ:PCSA) s
BenzingaApr 25 12:31 ET
KOPN, BTCM and CETX Among Mid-day Movers
Seeking AlphaApr 23 13:16 ET
Express News | Protagenic Therapeutics Q4 EPS $(0.38) Down From $(0.14) YoY
Moomoo 24/7Apr 2 08:10 ET
Earnings Call Summary | Protagenic Therapeutics(PTIX.US) Q4 2023 Earnings Conference
The following is a summary of the Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript:Financial Performance:Protagenic Therapeutics reported an increase in Research and Development (
moomoo AIApr 1 22:18 ET · Conference Call
Express News | Protagenic Therapeutics FY23 EPS $(1.15) Down From $(0.82) YoY
Moomoo 24/7Apr 1 16:24 ET
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Gene
AccesswireApr 1 16:20 ET
Earnings Scheduled For April 1, 2024
Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million. • Sharps Technology (NASDAQ:STSS) is
BenzingaApr 1 05:13 ET
Express News | Protagenic Therapeutics Successfully Concludes Third Cohort In Single Dose Portion Of Phase 1 Trial For Stress-Related Neuropsychiatric Disorders
Moomoo 24/7Mar 27 08:51 ET
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Next clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mis
AccesswireMar 27 08:42 ET
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ETNEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Com
AccesswireMar 25 17:00 ET
Express News | Protagenic Therapeutics Announces Resolution Of Nasdaq Deficiency Notice
Moomoo 24/7Mar 21 08:43 ET
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550 as the closing bid price of shares of PTIX
AccesswireMar 21 08:41 ET
EYEN, BYSI and FENG Among Mid-day Movers
Seeking AlphaMar 5 12:38 ET
Protagenic Advances in Stress Disorder Treatment Trial
InvestingFeb 13 08:44 ET
Express News | Protagenic Therapeutics Completes First Dose Escalation Step In Phase I Safety Clinical Trial For PT00114
Moomoo 24/7Feb 13 08:36 ET
Protagenic Therapeutics Achieves First Clinical Safety Milestone With Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Company Anticipates Reporting Complete Phase I Single Dose Results in AprilNEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, announced a step
AccesswireFeb 13 08:30 ET
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%
US stocks look set to open flat to slightly higher in Tuesday's trading session as investors parse inflation data that came out earlier in the morning and look to the start of the Federal Reserve's tw
MT NewswiresDec 12, 2023 09:25 ET
Protagonist Reports 2-Year Follow Up Data From Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia veraAnalysis o
AccesswireDec 12, 2023 07:30 ET
Protagenic Therapeutics(PTIX.US) Officer Buys US$6,480 in Common Stocks
$Protagenic Therapeutics(PTIX.US)$ Officer Arrow Alexander K. purchased 8,000 shares of Common Stocks on Oct 12, 2023 at an average price of $0.81 for a total value of $6,480.Source: Announcement What
moomoo NewsOct 13, 2023 13:27 ET
No Data
No Data